Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath in Relapsing or Refractory Non-Hodgkin's Lymphoma
NCT00051701Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in non-Hodgkin lymphoma (NHL), sponsored by Sanofi. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate. Started Dec 2002; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00051701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051701.